This ongoing multicenter, randomized phase III trial targets patients with postoperative recurrence of completely resected NSCLC, characterized by three or fewer distant metastases and no EGFR or ALK gene mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.